m6A-modified CTC-297N7.9 inhibits hepatocellular carcinoma metastasis via epigenetically downregulating CCL2 and CD47
Abstract Background Hepatocellular carcinoma (HCC) is one of most common malignancies with poor prognosis, largely due to its high propensity for metastasis and recurrence. As the most common internal RNA modification, N6-methyladenosine (m6A) plays critical and diverse roles in HCC progression. How...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Cancer Cell International |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12935-025-03857-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849761212474064896 |
|---|---|
| author | Huamei Wei Changhong Pu Min Zeng Rongzhou Lu Yunyu Wei Yanyan Huang Zheng Huang Lizheng Huang Zuoming Xu Jianchu Wang Rihai Ma Jian Pu |
| author_facet | Huamei Wei Changhong Pu Min Zeng Rongzhou Lu Yunyu Wei Yanyan Huang Zheng Huang Lizheng Huang Zuoming Xu Jianchu Wang Rihai Ma Jian Pu |
| author_sort | Huamei Wei |
| collection | DOAJ |
| description | Abstract Background Hepatocellular carcinoma (HCC) is one of most common malignancies with poor prognosis, largely due to its high propensity for metastasis and recurrence. As the most common internal RNA modification, N6-methyladenosine (m6A) plays critical and diverse roles in HCC progression. However, the mechanisms by which m6A regulates HCC metastasis remain incompletely understood. Here, we aimed to identify key m6A modification events during HCC metastasis. Methods The expression of CTC-297N7.9. was measured by qPCR. m6A modification level of CTC-297N7.9 was measured by methylated RNA immunoprecipitation (MeRIP) and single-base elongation- and ligation-based qPCR amplification method (SELECT). The roles of m6A-modified CTC-297N7.9 in HCC were investigated by in vitro cell viability, proliferation, migration and phagocytosis assays, and in vivo liver metastasis and lung metastasis assays. The underlying mechanisms of m6A-modified CTC-297N7.9 were dissected by chromatin isolation by RNA purification (ChIRP), assay for transposase accessible chromatin (ATAC) and cleavage under target & tagmentation (CUT&Tag) assays. Results The m6A modification level of CTC-297N7.9 is decreased in HCC tissues and correlated with microvascular invasion and poor prognosis. CTC-297N7.9 suppresses HCC metastasis in an m6A-dependent manner. m6A-modified CTC-297N7.9 attenuates tumor-associated macrophages (TAMs) infiltration and M2 polarization through downregulating CCL2 expression and secretion. Additionally, m6A-modified CTC-297N7.9 promotes phagocytosis of HCC cells by macrophages through downregulating the phagocytosis checkpoint CD47. Mechanistic investigations revealed that m6A-modified CTC-297N7.9 binds the m6A reader YTHDC1, which further binds and recruits the histone H3K9me3 methyltransferase SETDB1 and H3K27me3 methyltransferase EZH2 to the promoters of CCL2 and CD47, leading to the upregulation of H3K9me3 and H3K27me3 modifications at CCL2 and CD47 promoters, and transcriptional silencing of CCL2 and CD47. Conclusions Our study demonstrates that m6A-modified CTC-297N7.9 acts as a metastasis suppressor in HCC, and highlights its potential as a prognostic biomarker and therapeutic target for HCC. |
| format | Article |
| id | doaj-art-dc8f68e3f0da45fc8a0a1a72cb05d1da |
| institution | DOAJ |
| issn | 1475-2867 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Cell International |
| spelling | doaj-art-dc8f68e3f0da45fc8a0a1a72cb05d1da2025-08-20T03:06:06ZengBMCCancer Cell International1475-28672025-07-0125111910.1186/s12935-025-03857-0m6A-modified CTC-297N7.9 inhibits hepatocellular carcinoma metastasis via epigenetically downregulating CCL2 and CD47Huamei Wei0Changhong Pu1Min Zeng2Rongzhou Lu3Yunyu Wei4Yanyan Huang5Zheng Huang6Lizheng Huang7Zuoming Xu8Jianchu Wang9Rihai Ma10Jian Pu11Department of Pathology, Affiliated Hospital of Youjiang Medical University for NationalitiesDepartment of Radiology, Affiliated Hospital of Youjiang Medical University for NationalitiesGraduate College of Youjiang Medical University for NationalitiesGraduate College of Youjiang Medical University for NationalitiesGraduate College of Youjiang Medical University for NationalitiesGraduate College of Youjiang Medical University for NationalitiesGraduate College of Youjiang Medical University for NationalitiesGraduate College of Youjiang Medical University for NationalitiesDepartment of Hepatobiliary Surgery, Affiliated Hospital of Youjiang Medical University for NationalitiesGuangxi Clinical Medical Research Center of Hepatobiliary DiseaseDepartment of Hepatobiliary Surgery, Affiliated Hospital of Youjiang Medical University for NationalitiesGuangxi Clinical Medical Research Center of Hepatobiliary DiseaseAbstract Background Hepatocellular carcinoma (HCC) is one of most common malignancies with poor prognosis, largely due to its high propensity for metastasis and recurrence. As the most common internal RNA modification, N6-methyladenosine (m6A) plays critical and diverse roles in HCC progression. However, the mechanisms by which m6A regulates HCC metastasis remain incompletely understood. Here, we aimed to identify key m6A modification events during HCC metastasis. Methods The expression of CTC-297N7.9. was measured by qPCR. m6A modification level of CTC-297N7.9 was measured by methylated RNA immunoprecipitation (MeRIP) and single-base elongation- and ligation-based qPCR amplification method (SELECT). The roles of m6A-modified CTC-297N7.9 in HCC were investigated by in vitro cell viability, proliferation, migration and phagocytosis assays, and in vivo liver metastasis and lung metastasis assays. The underlying mechanisms of m6A-modified CTC-297N7.9 were dissected by chromatin isolation by RNA purification (ChIRP), assay for transposase accessible chromatin (ATAC) and cleavage under target & tagmentation (CUT&Tag) assays. Results The m6A modification level of CTC-297N7.9 is decreased in HCC tissues and correlated with microvascular invasion and poor prognosis. CTC-297N7.9 suppresses HCC metastasis in an m6A-dependent manner. m6A-modified CTC-297N7.9 attenuates tumor-associated macrophages (TAMs) infiltration and M2 polarization through downregulating CCL2 expression and secretion. Additionally, m6A-modified CTC-297N7.9 promotes phagocytosis of HCC cells by macrophages through downregulating the phagocytosis checkpoint CD47. Mechanistic investigations revealed that m6A-modified CTC-297N7.9 binds the m6A reader YTHDC1, which further binds and recruits the histone H3K9me3 methyltransferase SETDB1 and H3K27me3 methyltransferase EZH2 to the promoters of CCL2 and CD47, leading to the upregulation of H3K9me3 and H3K27me3 modifications at CCL2 and CD47 promoters, and transcriptional silencing of CCL2 and CD47. Conclusions Our study demonstrates that m6A-modified CTC-297N7.9 acts as a metastasis suppressor in HCC, and highlights its potential as a prognostic biomarker and therapeutic target for HCC.https://doi.org/10.1186/s12935-025-03857-0N6-methyladenosineHepatocellular carcinomaMetastasisMacrophagePhagocytosisEpigenetic modulation |
| spellingShingle | Huamei Wei Changhong Pu Min Zeng Rongzhou Lu Yunyu Wei Yanyan Huang Zheng Huang Lizheng Huang Zuoming Xu Jianchu Wang Rihai Ma Jian Pu m6A-modified CTC-297N7.9 inhibits hepatocellular carcinoma metastasis via epigenetically downregulating CCL2 and CD47 Cancer Cell International N6-methyladenosine Hepatocellular carcinoma Metastasis Macrophage Phagocytosis Epigenetic modulation |
| title | m6A-modified CTC-297N7.9 inhibits hepatocellular carcinoma metastasis via epigenetically downregulating CCL2 and CD47 |
| title_full | m6A-modified CTC-297N7.9 inhibits hepatocellular carcinoma metastasis via epigenetically downregulating CCL2 and CD47 |
| title_fullStr | m6A-modified CTC-297N7.9 inhibits hepatocellular carcinoma metastasis via epigenetically downregulating CCL2 and CD47 |
| title_full_unstemmed | m6A-modified CTC-297N7.9 inhibits hepatocellular carcinoma metastasis via epigenetically downregulating CCL2 and CD47 |
| title_short | m6A-modified CTC-297N7.9 inhibits hepatocellular carcinoma metastasis via epigenetically downregulating CCL2 and CD47 |
| title_sort | m6a modified ctc 297n7 9 inhibits hepatocellular carcinoma metastasis via epigenetically downregulating ccl2 and cd47 |
| topic | N6-methyladenosine Hepatocellular carcinoma Metastasis Macrophage Phagocytosis Epigenetic modulation |
| url | https://doi.org/10.1186/s12935-025-03857-0 |
| work_keys_str_mv | AT huameiwei m6amodifiedctc297n79inhibitshepatocellularcarcinomametastasisviaepigeneticallydownregulatingccl2andcd47 AT changhongpu m6amodifiedctc297n79inhibitshepatocellularcarcinomametastasisviaepigeneticallydownregulatingccl2andcd47 AT minzeng m6amodifiedctc297n79inhibitshepatocellularcarcinomametastasisviaepigeneticallydownregulatingccl2andcd47 AT rongzhoulu m6amodifiedctc297n79inhibitshepatocellularcarcinomametastasisviaepigeneticallydownregulatingccl2andcd47 AT yunyuwei m6amodifiedctc297n79inhibitshepatocellularcarcinomametastasisviaepigeneticallydownregulatingccl2andcd47 AT yanyanhuang m6amodifiedctc297n79inhibitshepatocellularcarcinomametastasisviaepigeneticallydownregulatingccl2andcd47 AT zhenghuang m6amodifiedctc297n79inhibitshepatocellularcarcinomametastasisviaepigeneticallydownregulatingccl2andcd47 AT lizhenghuang m6amodifiedctc297n79inhibitshepatocellularcarcinomametastasisviaepigeneticallydownregulatingccl2andcd47 AT zuomingxu m6amodifiedctc297n79inhibitshepatocellularcarcinomametastasisviaepigeneticallydownregulatingccl2andcd47 AT jianchuwang m6amodifiedctc297n79inhibitshepatocellularcarcinomametastasisviaepigeneticallydownregulatingccl2andcd47 AT rihaima m6amodifiedctc297n79inhibitshepatocellularcarcinomametastasisviaepigeneticallydownregulatingccl2andcd47 AT jianpu m6amodifiedctc297n79inhibitshepatocellularcarcinomametastasisviaepigeneticallydownregulatingccl2andcd47 |